Arbutus announces multiple abstracts accepted for AASLD 2023, including late-breaking imdusiran data

Arbutus Biopharma Corp

Late-breaking poster on imdusiran (AB-729) followed by VTP-300 or placebo in chronic hepatitis B subjects.
Poster #1459-C shows baseline HBV SNPs do not impact HBsAg reductions from imdusiran.
Oral presentation on 48-week vebicorvir + imdusiran + NrtI combination in eAg-negative CHB (Nov 12).
Preclinical data on oral small-molecule liver-tropic PD-L1 inhibitor for HCC (Nov 13).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.